Passage Bio, Inc. Profile Avatar - Palmy Investing

Passage Bio, Inc.

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene …

Biotechnology
US, Philadelphia [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of PASG's Analysis
CIK: 1787297 CUSIP: 702712100 ISIN: US7027121000 LEI: - UEI: -
Secondary Listings
PASG has no secondary listings inside our databases.